Automate Your Wheel Strategy on DHR
With Tiblio's Option Bot, you can configure your own wheel strategy including DHR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DHR
- Rev/Share 33.2542
- Book/Share 70.9996
- PB 2.8309
- Debt/Equity 0.324
- CurrentRatio 1.4334
- ROIC 0.0553
- MktCap 143821043200.0
- FreeCF/Share 6.8435
- PFCF 29.3393
- PE 38.2331
- Debt/Assets 0.2083
- DivYield 0.0072
- ROE 0.0747
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | DHR | Barclays | Equal Weight | Overweight | -- | $205 | April 10, 2025 |
| Upgrade | DHR | Goldman | Neutral | Buy | -- | $260 | March 21, 2025 |
| Upgrade | DHR | Stifel | Hold | Buy | -- | $260 | March 14, 2025 |
| Downgrade | DHR | Raymond James | Outperform | Market Perform | -- | -- | Feb. 3, 2025 |
| Initiation | DHR | Scotiabank | -- | Sector Perform | -- | -- | Dec. 23, 2024 |
| Initiation | DHR | Guggenheim | -- | Buy | -- | $275 | Dec. 19, 2024 |
| Upgrade | DHR | BofA Securities | Neutral | Buy | -- | $290 | Dec. 13, 2024 |
| Initiation | DHR | Stephens | -- | Overweight | -- | $315 | Oct. 1, 2024 |
| Initiation | DHR | Wells Fargo | -- | Equal Weight | -- | $280 | Aug. 28, 2024 |
News
CVS vs. DHR: Which Stock Is the Better Value Option?
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in stocks from the Medical Services sector have probably already heard of CVS Health (CVS) and Danaher (DHR). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Why Danaher (DHR) is a Top Growth Stock for the Long-Term
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Danaher: High Capex And Low Debt Despite Trump Legislation
Published: June 19, 2025 by: Seeking Alpha
Sentiment: Positive
The company has achieved returns on equity above 7.8% since 2019. Additionally, it reduced its liabilities-to-assets ratio to 35.72% this quarter, indicating a low risk of bankruptcy. Danaher expects an excellent growth outlook in the upcoming years, due to the significant investment that the biopharma industry has dedicated to developing new medical therapies. Between 2017 and 2024, Danaher invested 25.81% of its revenues to expand its operations, which has contributed to the growth rate of its revenues.
Read More
CVS vs. DHR: Which Stock Should Value Investors Buy Now?
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical Services stocks have likely encountered both CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Read More
Software Launches for SCIEX OS Ecosystem to Help Scientists Accelerate Discoveries and Streamline Lab Operations
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #AI--SCIEX announces three software ecosystem enhancements at ASMS, supporting the theme that “all science is data science now.”.
Read More
SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #ZenoTOF--At ASMS 2025, SCIEX launches the ZenoTOF 8600 system, setting a new standard in accurate mass quantitation.
Read More
SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #Evocep--SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement.
Read More
Danaher Partners With AstraZeneca to Support Precision Medicine
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient selection and making advanced tests accessible worldwide.
Read More
CVS or DHR: Which Is the Better Value Stock Right Now?
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical Services sector have probably already heard of CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Read More
Why Is Danaher (DHR) Down 4.8% Since Last Earnings Report?
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Negative
Danaher (DHR) reported earnings 30 days ago. What's next for the stock?
Read More
Here's Why Investors Should Consider Retaining Danaher Stock Now
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Positive
DHR gains from strength across its businesses, acquired assets and shareholder-friendly policies. High long-term debt remains concerning.
Read More
Danaher Corporation (DHR) BofA Securities 2025 Healthcare Conference (Transcript)
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral
Danaher Corporation (NYSE:DHR ) BofA Securities 2025 Healthcare Conference May 15, 2025 1:00 PM ET Company Participants Rainer Blair - CEO Conference Call Participants Mike Ryskin - Bank of America Mike Ryskin My name is Mike Ryskin. I'm on the Bank of America Life Science Tools and Diagnostics team and I'm excited to host our next session.
Read More
CVS vs. DHR: Which Stock Is the Better Value Option?
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical Services sector might want to consider either CVS Health (CVS) or Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Danaher: A Capital Intensive Business Offering Low Risk, Low Reward Opportunity
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Positive
Danaher Corporation's intrinsic value is estimated at $213 per share, suggesting a 14% upside from the current price of $187, with a 12% margin of safety. Despite revenue growth driven by acquisitions, Danaher's heavy reliance on debt and declining ROIC indicate challenges in capital efficiency and operational performance. The company's high capital intensity, slow growth, and mounting debt levels make its near-term investment potential pessimistic, despite a diversified portfolio.
Read More
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Positive
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts.
Read More
BLCO or DHR: Which Is the Better Value Stock Right Now?
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Danaher (DHR). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Danaher Q1 Earnings Beat Estimates, Life Sciences Sales Down Y/Y
Published: April 22, 2025 by: Zacks Investment Research
Sentiment: Neutral
DHR's first-quarter sales decrease 1% year over year, due to the lackluster performance of its Life Sciences and Biotechnology segments.
Read More
Danaher (DHR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: April 22, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Danaher Reports First Quarter 2025 Results
Published: April 22, 2025 by: PRNewsWire
Sentiment: Neutral
WASHINGTON , April 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 28, 2025. Key First Quarter 2025 Results Net earnings were $1.0 billion, or $1.32 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.88.
Read More
Danaher Gears Up to Post Q1 Earnings: Is a Beat in Store?
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Neutral
DHR's first-quarter earnings are likely to have been aided by strength in the Biotechnology segment. However, weakness in the Diagnostics and Life Sciences segments are expected to have hurt.
Read More
Danaher Gains From Strength in the Diagnostics Unit Amid Headwinds
Published: April 04, 2025 by: Zacks Investment Research
Sentiment: Positive
DHR is poised to gain from strength in the clinical diagnostics business, the Abcam buyout and shareholder-friendly policies. Softness in Life Sciences and Biotechnology units remains a concern.
Read More
Danaher Corporation (DHR) TD Cowen 45th Annual Health Care Conference Transcript
Published: March 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Danaher Corporation (NYSE:DHR ) TD Cowen 45th Annual Health Care Conference Call March 5, 2025 10:30 AM ET Company Participants Rainer Blair – President and Chief Executive Officer Conference Call Participants Dan Brennan – TD Cowen Dan Brennan Welcome to day-three of the TD Cowen Global Healthcare Conference. I'm Dan Brennan, I follow tools and diagnostics.
Read More
Danaher Rewards Shareholders With 18.5% Dividend Increase
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
DHR's measures to consistently reward shareholders through dividends and share buybacks hold promise.
Read More
Industrial Laser Marking Machine Market To Reach USD 6.41 Billion by 2032, Growing at CAGR 8.1% | Coherent, Inc., Danaher Corporation, Epilog Laser
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
An industrial laser marking machine uses laser technology to engrave, etch, or mark materials with precision for identification, branding, or tracking. An industrial laser marking machine uses laser technology to engrave, etch, or mark materials with precision for identification, branding, or tracking.
Read More
3 Stocks Offering Strong Value and Stability
Published: February 24, 2025 by: MarketBeat
Sentiment: Positive
Though not as safe a bet as safe-haven assets like precious metals, value stocks are nonetheless an enticing option for investors when the market gets bumpy. An undervalued company that has excellent fundamentals but a less-than-stellar recent stock performance history is often better positioned to benefit during periods of volatility than growth names with less of a track record of success.
Read More
Danaher Announces Appointment of Charles Lamanna to Danaher Board
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral
WASHINGTON , Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that it has appointed Charles Lamanna to its Board of Directors and to the Board's Science & Technology Committee. Mr. Lamanna is currently Corporate Vice President, Business & Industry Copilot at Microsoft (NASDAQ: MSFT), where he drives product innovation in AI-powered business applications, low-code platforms, and autonomous agents.
Read More
Danaher: Self-Inflicted Pessimism?
Published: February 17, 2025 by: Seeking Alpha
Sentiment: Positive
Danaher Corp. has faced market punishment recently, but maintains strong margins and impressive FCF despite a tough year, indicating resilience and potential for future growth. The company's strategic capital allocation, including share buybacks and acquisitions, suggests management is positioning for long-term value creation, despite short-term pessimism. Danaher's bioprocessing segment shows consistent growth, and the upcoming patent cliff is expected to provide significant tailwinds, boosting demand for their life science equipment.
Read More
All-In: The 23-Stock Six-Figure Dividend Portfolio I'm Betting My Future On
Published: February 14, 2025 by: Seeking Alpha
Sentiment: Positive
Thank you to the Seeking Alpha community for your support! Reaching 40,000 followers is a dream come true. Your feedback fuels my work. I've invested 91% of my net worth in 23 high-conviction dividend stocks. Focused on wide-moat businesses, I prioritize quality and long-term growth over yield. My portfolio has outperformed the S&P 500, and I'm confident in its future. I expect a rotation to value stocks, and I'll keep sharing insights to grow together.
Read More
About Danaher Corporation (DHR)
- IPO Date 1978-12-29
- Website https://www.danaher.com
- Industry Medical - Diagnostics & Research
- CEO Rainer M. Blair
- Employees 61000